Hims & Hers Health reported third-quarter results that topped Street expectations Monday and said it plans to release a ...

Novo Nordisk's valuation remains high, trading at a significant historical premium. Click here to see why NVO stock is a Sell ...

Telehealth company Hims & Hers said late Monday in an earnings update that it plans to launch a generic version of Novo ...

Hims & Hers Health (HIMS) stock gains after its Q3 2024 results as company plans to launch a generic version of Novo ...

The Danish drug company Novo Nordisk has been sanctioned by the UK pharmaceutical industry regulator over the way it has ...

The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versions of ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

Hims & Hers currently offers compounded GLP-1 weight-loss injections at $199 per month and weight management oral medication ...

The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a ...

Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report on the performance of its ...

Novo Nordisk addresses safety concerns surrounding compounded versions of its weight-loss and diabetes drugs, including ...